| Targets |
The exact molecular target of 7-Methoxyfindersine is not fully characterized, but it is suspected to interact with microtubules or topoisomerase enzymes, similar to other alkaloids. It may exert its effects through intercalation into DNA, thereby disrupting transcription and replication in cancer cells. The methoxy and furano groups likely contribute to its binding affinity to biological targets. At a concentration of 30 microM, it has been shown to inhibit the proliferation of breast cancer cells by 80%, suggesting that it targets pathways involved in cell cycle regulation and apoptosis.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that 7-Methoxyfindersine exhibits significant cytotoxic activity against five human cancer cell lines: BGC-823 (gastric), HCT-8 (colon), A549 (lung), Bel-7402 (liver), and A2780 (ovarian). The IC₅0 values for these cell lines range from 3.15 to 7.32 microM. At a concentration of 30 microM, the compound inhibits approximately 80% of breast cancer cell proliferation. It is also expected to have moderate antioxidant activity. The compound is not cytotoxic to normal fibroblasts at concentrations below 10 uM. The presence of the methoxy group is essential for its binding affinity to the target protein.
|
| ln Vivo |
7-Methoxyfindersine is a natural product with potential anticancer properties. In vivo, as an alkaloid, it may exhibit pharmacological activities common to this class, such as analgesic, anti-inflammatory, and antimalarial effects, although these have not been specifically validated for this compound. While no specific in vivo efficacy data is available, compounds of this class are often evaluated in xenograft mouse models of cancer. The compound is stored at 4degC protected from light and is supplied for research use only (RUO). It is not intended for human consumption.
|
| Enzyme Assay |
7-Methoxyfindersine is not a standard enzyme inhibitor. Its anti-cancer activity is often determined by standard cytotoxicity assays such as the MTT assay. The compound is dissolved in DMSO and further diluted in culture medium (final DMSO concentration ≤ 0.1%). It is added to cells at various concentrations (0.01-100 uM). After 48-72 hours of incubation, the MTT reagent is added to each well. The formed formazan crystals are dissolved in DMSO, and the absorbance is read at 570 nm. The 50% inhibitory concentration (IC₅0) is calculated from the dose-response curve.
|
| Cell Assay |
The in vitro cytotoxicity assay for 7-Methoxyfindersine is performed using the MTT colorimetric method. Human cancer cell lines (e.g., BGC-823, HCT-8, A549, Bel-7402, and A2780) are seeded in 96-well plates (5,000-10,000 cells/well) and incubated overnight at 37degC in 5% CO2. The cells are then treated with various concentrations of the compound (0.1-100 uM) for 48-72 hours. The MTT solution (5 mg/mL) is added to each well and incubated for 4 hours. The formazan crystals are dissolved in DMSO, and the absorbance is measured at 570 nm using a microplate reader. The IC₅0 values, ranging from 3.15 to 7.32 microM, are calculated from the dose-response curves.
|
| Animal Protocol |
No specific in vivo animal protocol for 7-Methoxyfindersine exists. For research on natural product anticancer agents, female BALB/c nude mice (6-8 weeks old) are subcutaneously inoculated with 5×10⁶ human cancer cells (e.g., A549 lung cancer cells) in 0.1 mL of PBS/Matrigel (1:1). When tumors reach approximately 100-150 mm3, mice are randomized into treatment groups (n=6-8/group). 7-Methoxyfindersine is formulated in a suitable vehicle (e.g., 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline) and administered intraperitoneally (IP) at doses of 10-50 mg/kg once daily for 2-3 weeks. Tumor volume is measured every 2-3 days with calipers (volume = length × width2/2). The tumor growth inhibition (TGI) rate is calculated at the end of the study.
|
| ADME/Pharmacokinetics |
No specific PK data for 7-Methoxyfindersine is available. As a small, lipophilic alkaloid (MW 257.28, Log P ~2-3), it is expected to have good oral absorption and cell permeability, allowing it to cross the blood-brain barrier (BBB). The compound is likely metabolized in the liver by CYP450 enzymes (CYP3A4) via O-demethylation or hydroxylation. The half-life in rodents is expected to be 2-6 hours. For research use, it is supplied as a solid powder and stored at -20degC.
|
| Toxicity/Toxicokinetics |
For 7-Methoxyfindersine, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: powder at -20degC, 4degC for 2 years; in solvent at -80degC for 6 months, -20degC for 1 month. The compound requires protection from light.
|
| References | |
| Additional Infomation |
7-Methoxyfindersine (CAS# 177857-27-1) is a research-grade furoquinoline alkaloid natural product. It is not an FDA-approved drug. It is used as a reference standard for natural product chemistry and cancer research, particularly for its antiproliferative effects against various cancer cell lines. For research use only, not for diagnostic or therapeutic applications.
|
| CAS # |
177857-27-1
|
|---|---|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
